Officer sold ~$1.12M of Vertex Pharmaceuticals
Scheduled in advanceLoading…
Traded Feb 17, 2026 · Filed Feb 19, 2026
Vertex Pharmaceuticals's Chief Scientific Officer sold $1.19M of Vertex Pharmaceuticals shares. It was planned long ago, so it says very little.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$1,192,814
Shares × reported transaction price
5 days after results of Feb 12, 2026, 76 days before results of May 4, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $477.32 on Feb 17, 2026, 30% above its 52-week low and 7% below its high, after a 6% rise over the previous 30 trading days
52-week range $366.54 (Aug 8, 2025) to $513.76 (Mar 17, 2025), 75% of the way up, from 251 adjusted closes. 30 trading days earlier: $452.13 on Jan 2, 2026. Describes the past only, not a forecast
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +4.2% | -0.5% | +4.7% |
| 30 days | -5.4% | -4.9% | -0.4% |
| 90 days | -9.1% | +7.7% | -16.8% |
| 180 days | +15.8% | +11.6% | +4.2% |
Past results only. Not a forecast.
Officer sold ~$1.12M of Vertex Pharmaceuticals
Scheduled in advanceOfficer sold ~$1.31M of Vertex Pharmaceuticals
Scheduled in advanceOfficer sold ~$1.16M of Vertex Pharmaceuticals
Scheduled in advance